PE20091628A1 - Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona - Google Patents
Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-onaInfo
- Publication number
- PE20091628A1 PE20091628A1 PE2009000395A PE2009000395A PE20091628A1 PE 20091628 A1 PE20091628 A1 PE 20091628A1 PE 2009000395 A PE2009000395 A PE 2009000395A PE 2009000395 A PE2009000395 A PE 2009000395A PE 20091628 A1 PE20091628 A1 PE 20091628A1
- Authority
- PE
- Peru
- Prior art keywords
- benzimidazol
- methylpiperazin
- quinolin
- fluoro
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3774608P | 2008-03-19 | 2008-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091628A1 true PE20091628A1 (es) | 2009-11-19 |
Family
ID=40622140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000395A PE20091628A1 (es) | 2008-03-19 | 2009-03-17 | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
Country Status (25)
Country | Link |
---|---|
US (1) | US8563556B2 (zh) |
EP (1) | EP2257544B1 (zh) |
JP (1) | JP2011515370A (zh) |
KR (1) | KR20100137517A (zh) |
CN (1) | CN101970425B (zh) |
AR (1) | AR070924A1 (zh) |
AU (1) | AU2009227003B2 (zh) |
BR (1) | BRPI0909762A2 (zh) |
CA (1) | CA2718076A1 (zh) |
CL (1) | CL2009000651A1 (zh) |
CO (1) | CO6321253A2 (zh) |
EC (1) | ECSP10010555A (zh) |
HK (1) | HK1147492A1 (zh) |
IL (1) | IL208020A0 (zh) |
MA (1) | MA32230B1 (zh) |
MX (1) | MX2010010152A (zh) |
MY (1) | MY150554A (zh) |
NZ (2) | NZ600887A (zh) |
PE (1) | PE20091628A1 (zh) |
PH (2) | PH12012502569A1 (zh) |
RU (1) | RU2497820C2 (zh) |
SG (1) | SG188919A1 (zh) |
TW (1) | TWI426072B (zh) |
WO (1) | WO2009115562A2 (zh) |
ZA (1) | ZA201006263B (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
TR201819653T4 (tr) | 2010-04-16 | 2019-01-21 | Novartis Ag | Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik. |
RU2012148706A (ru) | 2010-04-16 | 2014-05-27 | Новартис Аг | Комбинация органичемких соединений |
UY33472A (es) * | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
SG192962A1 (en) | 2011-03-17 | 2013-09-30 | Novartis Ag | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects |
KR20140023358A (ko) | 2011-05-19 | 2014-02-26 | 노파르티스 아게 | 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 |
US20140221389A1 (en) | 2011-09-15 | 2014-08-07 | Novartis Ag | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
JP2015505562A (ja) | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Rtk阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
US20150202203A1 (en) | 2012-07-11 | 2015-07-23 | Novartis Ag | Method of Treating Gastrointestinal Stromal Tumors |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3116909B1 (en) | 2014-03-14 | 2019-11-13 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
WO2016145102A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
EP4046655A1 (en) | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1317442T3 (da) | 2000-09-11 | 2006-02-13 | Chiron Corp | Quinolinonderivater som tyrosinkinaseinhibitorer |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
KR20050037585A (ko) | 2002-08-23 | 2005-04-22 | 카이론 코포레이션 | 벤지미다졸 퀴놀리논 및 그들의 사용 |
US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
JP2006511616A (ja) * | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | 癌の処置方法およびその関連方法 |
CN100377709C (zh) * | 2002-11-13 | 2008-04-02 | 希龙公司 | 受体酪氨酸激酶抑制剂的制药用途及相关检测方法 |
JP4890255B2 (ja) * | 2003-11-07 | 2012-03-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩 |
WO2005082340A2 (en) * | 2004-02-20 | 2005-09-09 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
DK1845990T3 (da) * | 2005-01-27 | 2012-01-02 | Novartis Vaccines & Diagnostic | Behandling af metastaserede tumorer |
US20110178097A1 (en) * | 2005-05-23 | 2011-07-21 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
MY148529A (en) | 2005-11-29 | 2013-04-30 | Novartis Ag | Formulations of quinolinones |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
-
2009
- 2009-03-17 AR ARP090100957A patent/AR070924A1/es unknown
- 2009-03-17 PE PE2009000395A patent/PE20091628A1/es not_active Application Discontinuation
- 2009-03-18 RU RU2010142396/04A patent/RU2497820C2/ru not_active IP Right Cessation
- 2009-03-18 SG SG2013020011A patent/SG188919A1/en unknown
- 2009-03-18 CA CA2718076A patent/CA2718076A1/en not_active Abandoned
- 2009-03-18 BR BRPI0909762A patent/BRPI0909762A2/pt not_active IP Right Cessation
- 2009-03-18 CL CL2009000651A patent/CL2009000651A1/es unknown
- 2009-03-18 WO PCT/EP2009/053222 patent/WO2009115562A2/en active Application Filing
- 2009-03-18 US US12/922,213 patent/US8563556B2/en not_active Expired - Fee Related
- 2009-03-18 JP JP2011500221A patent/JP2011515370A/ja active Pending
- 2009-03-18 MX MX2010010152A patent/MX2010010152A/es not_active Application Discontinuation
- 2009-03-18 KR KR1020107023196A patent/KR20100137517A/ko not_active Application Discontinuation
- 2009-03-18 EP EP09721534.7A patent/EP2257544B1/en active Active
- 2009-03-18 CN CN200980108402.0A patent/CN101970425B/zh not_active Expired - Fee Related
- 2009-03-18 TW TW098108804A patent/TWI426072B/zh not_active IP Right Cessation
- 2009-03-18 MY MYPI20104156 patent/MY150554A/en unknown
- 2009-03-18 AU AU2009227003A patent/AU2009227003B2/en not_active Ceased
- 2009-03-18 NZ NZ600887A patent/NZ600887A/xx not_active IP Right Cessation
- 2009-03-18 NZ NZ587829A patent/NZ587829A/xx not_active IP Right Cessation
-
2010
- 2010-09-01 ZA ZA2010/06263A patent/ZA201006263B/en unknown
- 2010-09-06 IL IL208020A patent/IL208020A0/en not_active IP Right Cessation
- 2010-10-15 MA MA33250A patent/MA32230B1/fr unknown
- 2010-10-19 CO CO10129430A patent/CO6321253A2/es not_active Application Discontinuation
- 2010-10-19 EC EC2010010555A patent/ECSP10010555A/es unknown
-
2011
- 2011-02-18 HK HK11101661.3A patent/HK1147492A1/zh not_active IP Right Cessation
-
2012
- 2012-12-26 PH PH12012502569A patent/PH12012502569A1/en unknown
- 2012-12-26 PH PH12012502568A patent/PH12012502568A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI426072B (zh) | 2014-02-11 |
EP2257544A2 (en) | 2010-12-08 |
IL208020A0 (en) | 2010-12-30 |
US20110021536A1 (en) | 2011-01-27 |
CN101970425A (zh) | 2011-02-09 |
MA32230B1 (fr) | 2011-04-01 |
MX2010010152A (es) | 2010-10-25 |
SG188919A1 (en) | 2013-04-30 |
NZ587829A (en) | 2012-08-31 |
AU2009227003A1 (en) | 2009-09-24 |
WO2009115562A2 (en) | 2009-09-24 |
HK1147492A1 (zh) | 2011-08-12 |
EP2257544B1 (en) | 2014-12-03 |
MY150554A (en) | 2014-01-30 |
CL2009000651A1 (es) | 2010-07-19 |
AU2009227003B2 (en) | 2013-03-14 |
NZ600887A (en) | 2013-10-25 |
WO2009115562A3 (en) | 2009-11-26 |
AR070924A1 (es) | 2010-05-12 |
CO6321253A2 (es) | 2011-09-20 |
ZA201006263B (en) | 2011-05-25 |
PH12012502569A1 (en) | 2015-09-21 |
TW201000463A (en) | 2010-01-01 |
RU2497820C2 (ru) | 2013-11-10 |
PH12012502568A1 (en) | 2014-10-27 |
BRPI0909762A2 (pt) | 2018-04-03 |
KR20100137517A (ko) | 2010-12-30 |
JP2011515370A (ja) | 2011-05-19 |
CN101970425B (zh) | 2014-04-16 |
RU2010142396A (ru) | 2012-04-27 |
US8563556B2 (en) | 2013-10-22 |
ECSP10010555A (es) | 2010-11-30 |
CA2718076A1 (en) | 2009-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091628A1 (es) | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona | |
PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
CU20120169A7 (es) | Compuestos pirimidinílicos como inhibidores de la cinasa atr | |
PE20120083A1 (es) | Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a | |
PE20170146A1 (es) | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
MX2015011955A (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
MX2015012005A (es) | Inhibidores de bromodominio. | |
PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
CL2009000727A1 (es) | Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras. | |
PH12015501088A1 (en) | Dimeric compounds | |
GEP20186876B (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
CL2008002809A1 (es) | Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros. | |
MX364649B (es) | Composición antimicrobiana. | |
CL2014002181A1 (es) | Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. | |
MX347858B (es) | Composición antimicrobiana. | |
EA201591649A1 (ru) | Составы с органическими соединениями | |
MX347389B (es) | Composicion antimicrobiana. | |
MX343517B (es) | 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide. | |
PH12015500399A1 (en) | Azaindolines | |
PH12015500185A1 (en) | Azaheterocycles as bir2 and/or bir3 inhibitors | |
MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |